Overview
NICE is unable to make a recommendation on carfilzomib (Kyprolis) with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma in adults. This is because Amgen did not provide an evidence submission.
Last reviewed: 22 November 2022
Next review: We will review this decision if the company decides to make a submission.